A recently completed study from the Hamamatsu University School of Medicine in Japan has indicated that the addition of "olanzapine significantly improved nausea prevention in the overall and delayed phases in patients who received carboplatin." Further, carboplatin, which has been classified as a moderate emetogenic chemotherapy agent, was not seen to cause serious adverse events in patients that were administered this drug.
For further information, and to learn more about this study, click here.
Source mentioned:
Inui N, Suzuki T, Tanaka K, et al. Olanzapine Plus Triple Antiemetic Therapy for the Prevention of Carboplatin-Induced Nausea and Vomiting: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial. JCO; Published online 4 June 2024. DOI: https://doi.org/10.1200/JCO.24.00278
No comments:
Post a Comment